Circulating mediators of bone remodeling in psoriatic arthritis: Implications for disordered osteoclastogenesis and bone erosion

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Dalbeth, Nicola ^a,b   Pool, Bregina ^a   Smith, Timothy ^a   Callon, Karen E ^a   Lobo, Maria ^b   Taylor, William J ^c   Jones, Peter B ^d   Cornish, Jillian ^a   McQueen, Fiona M ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Auckland District Health Board ^*  (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; COLONY STIMULATING FACTOR 1; DICKKOPF 1 PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; BIOLOGICAL MARKER; DKK1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE EROSION; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HUMAN; HUMAN CELL; MALE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; BLOOD; BONE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; STEM CELL;

ADULT; AGED; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; STEM CELLS; YOUNG ADULT;

EID: 77955944811     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3123     Document Type: Article

References (32)

1. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673. 10.1002/art.21972, 16871531.
2. Taylor WJ, Porter GG, Helliwell PS. Operational definitions and observer reliability of the plain radiographic features of psoriatic arthritis. J Rheumatol 2003, 30:2645-2658.
3. Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, Baldi F, Filipponi P, Marcolongo R. Bone mineral density in patients with psoriatic arthritis. J Rheumatol 2001, 28:138-143.
4. Ly J, Pinto C, Doyle A, Dalbeth N, McQueen FM. Axial bone proliferation causing cervical myelopathy in the mutilans form of psoriatic arthritis despite peripheral bone erosion. Ann Rheum Dis 2009, 68:443-444. 10.1136/ard.2008.093617, 19213749.
5. Teitelbaum SL. Osteoclasts: what do they do and how do they do it?. Am J Pathol 2007, 170:427-435. 10.2353/ajpath.2007.060834, 1851862, 17255310.
6. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602. 10.1073/pnas.95.7.3597, 19881, 9520411.
7. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176. 10.1016/S0092-8674(00)81569-X, 9568710.
8. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001, 3:683-686. 10.1038/35083081, 11433302.
9. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494. 10.1056/NEJMoa030847, 14695408.
10. Morvan F, Boulukos K, Clement-Lacroix P, Roman S, Suc-Royer I, Vayssiere B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006, 21:934-945. 10.1359/jbmr.060311, 16753024.
11. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163. 10.1038/nm1538, 17237793.
12. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821-831. 153764, 12639988.
13. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Quarta L, Cirulli N, Mancini L, Corrado A, Grassi FR, Grano M. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol 2007, 212:47-55. 10.1002/path.2153, 17370327.
14. Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, Haas-Smith SA, Ritchlin CT. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008, 67:296-301. 10.1136/ard.2007.076091, 17967829.
15. Chiu YG, Shao T, Feng C, Mensah KA, Thullen M, Schwarz EM, Ritchlin CT. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther 2010, 12:R14. 10.1186/ar2915, 2875642, 20102624.
16. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005, 115:3418-3427. 10.1172/JCI26132, 1283943, 16294221.
17. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309. 10.1038/46303, 10580503.
18. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002, 46:785-792. 10.1002/art.10097, 11920416.
19. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299-1309. 10.1002/art.23417, 18438830.
20. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978, 157:238-244. 10.1159/000250839, 357213.
21. Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis: clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004, 43:790-794. 10.1093/rheumatology/keh198, 15113998.
22. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56:2698-2707. 10.1002/art.22805, 17665424.
23. Dalbeth N, Smith T, Nicolson B, Clark B, Callon K, Naot D, Haskard DO, McQueen FM, Reid IR, Cornish J. Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum 2008, 58:1854-1865. 10.1002/art.23488, 18512794.
24. Massey HM, Flanagan AM. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 1999, 106:167-170. 10.1046/j.1365-2141.1999.01491.x, 10444181.
25. Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman SA, Van G, Scully S, Qi M, Grisanti M, Dunstan C, Boyle WJ, Lacey DL. Characterization of osteoclast precursors in human blood. Br J Haematol 2000, 111:501-512. 10.1046/j.1365-2141.2000.02379.x, 11122091.
26. Williamson L, Dockerty JL, Dalbeth N, McNally E, Ostlere S, Wordsworth BP. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology (Oxford) 2004, 43:85-88. 10.1093/rheumatology/keg475, 13130147.
27. Docherty P, Mitchell MJ, MacMillan L, Mosher D, Barnes DC, Hanly JG. Magnetic resonance imaging in the detection of sacroiliitis. J Rheumatol 1992, 19:393-401.
28. Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62:150-158. 10.1002/art.27231, 20039407.
29. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444. 10.1038/345442a0, 2188141.
30. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL. c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 2003, 111:749-758. 151897, 12618529.
31. Maksymowych WP, Landewe R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ, El-Gabalawy H, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP, Bathon JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus VB, Kvien TK, Taylor WJ, Wells GA, van der Heijde D. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009, 36:1785-1791. 10.3899/jrheum.090346, 19671813.
32. Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, Landewe R, Ostergaard M, Taylor WJ, Christensen R, Tak PP, Boers M, Syversen SW, Bathon JM, Ritchlin CJ, Mease PJ, Bykerk VP, Garnero P, Geusens P, El-Gabalawy H, Aletaha D, Inman RD, Kraus VB, Kvien TK, van der Heijde D. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 2009, 36:1792-1799. 10.3899/jrheum090347, 19671814.